Investors & Media

Transformative science, targeted medicines

We are working to advanceĀ a deep pipeline of precision therapies, designed to allow patients to live longer, better lives. Our approach combines world-leading expertise in protein kinases with sound execution and an intense focus on discovery.

SEC filing details

Document Details

Filing Date
Aug 1, 2018
Document Date
Dec 31, 2017
Form Description
Amendment to a previously filed 10-K
Filing Group
Annual Filings
Company
Blueprint Medicines Corp.
Issuer
Blueprint Medicines Corp